Related Experiment Video
Updated: Aug 10, 2026
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
Published on: July 28, 2020
Murine neuroblastoma: further evaluation of the C1300 model with single antitumor agents
Abstract:
The murine C1300 neuroblastoma model has been evaluated as a possible model for children with widespread metastatic disease. Drug toxicity studies were conducted in adult A/J mice with various doses of antitumor agents. Adriamycin, BCNU, bleomycin, guanazole, acronycine, isophosphamide, DTIC, ICRF-159, cyclophosphamide, vincristine, and vinblastine were adminstered intraperitoneally to random groups of normal mice. After identification of appropriate doses, chemotherapy studies were conducted with varius regimens of drugs. Chemotherapy was administered to adult A/J mice when their subcutaneously implanted tumors measured 1.0-1.7 cm in diameter. Antitumor drugs can be classified into three groups according to drug efficacy. BCNU, cyclophosphamide, and isophosphamide were extremely active. Cytosine arabinoside was reported to be active against this murine tumor in a previous publication. Drugs with minimal activiyt which deserve further evaluation included adriamycin, guanazole, ICRF-159, DTIC, and vinblastine. Inactive drugs were acronycine, bleomycin, 5-fluorouracil, and vincristine. These experiments suggest that children with metastatic neuroblastoma may respond to cyclophosphamide, isophosphamide, and BCNU, while DTIC, adriamycin, ICRF-159, guanazole, and the vinca alkaloids may also be effective. The results suggest that agents selected by the C1300 model should be given adequate clinical trials.
Insights
The C1300 neuroblastoma mouse model identified effective chemotherapy drugs for metastatic disease. Cyclophosphamide, isophosphamide, and BCNU showed high efficacy, suggesting potential for pediatric neuroblastoma treatment.
Area of Science:
- Oncology
- Pharmacology
- Translational Medicine
Background:
- Neuroblastoma is a significant pediatric cancer, often presenting with metastatic disease.
- The C1300 murine neuroblastoma model offers a platform for preclinical evaluation of anticancer agents.
- Understanding drug efficacy in this model can guide clinical treatment strategies.
Purpose of the Study:
- To assess the efficacy of various antitumor agents using the C1300 murine neuroblastoma model.
- To identify potential chemotherapeutic drugs for treating widespread metastatic neuroblastoma in children.
Main Methods:
- Drug toxicity studies were performed in A/J mice to determine appropriate dosages.
- Chemotherapy efficacy was evaluated in mice with established subcutaneous C1300 tumors (1.0-1.7 cm).
- Antitumor agents were administered intraperitoneally, and their effects were categorized based on efficacy.
Main Results:
- BCNU (Carmustine), cyclophosphamide, and isophosphamide demonstrated extreme activity against the C1300 tumor.
- Adriamycin (Doxorubicin), guanazole, ICRF-159, DTIC (Dacarbazine), and vinblastine showed minimal activity, warranting further investigation.
- Acronycine, bleomycin, 5-fluorouracil, and vincristine were found to be inactive in this model.
Conclusions:
- The C1300 neuroblastoma model effectively predicts drug responses, highlighting cyclophosphamide, isophosphamide, and BCNU as highly promising for metastatic neuroblastoma.
- DTIC, adriamycin, ICRF-159, guanazole, and vinca alkaloids may also hold therapeutic potential.
- Agents identified through the C1300 model warrant thorough clinical trials for pediatric neuroblastoma.
